Evaluating subcutaneous implantable cardioverter defibrillators in hypertrophic cardiomyopathy: fewer complications without increased therapies

Back

EHRA Premium Access

Evaluating subcutaneous implantable cardioverter defibrillators in hypertrophic cardiomyopathy: fewer complications without increased therapies

Session: Implantable cardioverter-defibrillator therapy

Topic: Implantable Cardioverter-Defibrillator (ICD)

Speaker: Mr C. Monkhouse (London, GB)

Event: EHRA 2025

Congress Presentation

Add to my library

About the speaker

Mr Christopher Monkhouse

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

1 presentation

0 follower

5 more presentations in this session

Comparison of newly detected atrial high-rate episodes incidence in single-lead ICDs with a floating atrial dipole and dual-chamber ICDs: a propensity score-matched analysis from the HMEA project

Speaker: Doctor G. Mitacchione (Brescia, IT)

Single- versus dual-chamber ICD discriminators for tachyarrhythmia detection: a remote monitoring based, single-center study

Speaker: Doctor F. Gausz (Szeged, HU)

Implantable cardioverter-defibrillator therapies in primary prevention are not decreased in a contemporary cohort: insights from long-term follow-up

Speaker: Doctor I. Ferreira Neves (Lisboa, PT)

In silico modeling of cardiac defibrillation with novel deep septal ICD leads

Speaker: Doctor G. Imnadze (Bad Oeynhausen, DE)

First real-world assessment of the extravascular implantable cardioverter-defibrillator: periprocedural outcomes from the Enlighten post-market study and comparison to a pre-market cohort

Speaker: Professor L. Boersma (Nieuwegein, NL)

Access the full session

Implantable cardioverter-defibrillator therapy

Speakers: Mr C. Monkhouse, Doctor G. Mitacchione, Doctor F. Gausz, Doctor I. Ferreira Neves, Doctor G. Imnadze...

Access

About the event

EHRA 2025

30 March - 1 April 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources